What did I learn from being a panelist at this #PAD session? A lot.

@baileyannRN @JVargheseMD @herbaronowMD @marcreixell @KimGSmolderen #acc23 @MarcBonaca

#PAD - the forgotten #ASCVD component.

🦵🏾MI/CVA events higher in PAD than in prior MI/CVA pts!!!!
🦵🏾Low use of statins/other LLT in PAD 👀😮
🦵🏾#LLT effective in PAD: statinize!

#acc23

What about antithrombolytics in #PAD?

🩸 Risk for MACE/MALE ⬆️w/presence of polyvasc and/or sx/event.
🩸ASA may help, crosses unity line tho
🩸p2y12 helps, modestly - ticag may not be better than clopido

#ACC23

More on anti-thrombo

🩸Too bad vorapaxar went away
🩸arterial thrombosis: platelet activation + thrombus (dual pathway inhibition)
🩸Read Compass! Not just #PAD, but CAD (90% had it)=24% RRR on rivaroxaban👊🏾
🩸Voyager: early separation (3m), ongoing divergence.
#ACC23

Antithombotics are no joke. More on board = more bleed risk.

🩸#PAD also is no joke. ⬆️⬆️ events. AntiThrombo help ⬇️events
🩸consider adding anticoag to antiplt (voyager/compass) in both PAD and/or CAD
🩸would love to hear thoughts on p2y12i+Xa rather than ASA+Xa
#ACC23